Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Articles with Puma Biotechnology | page 2
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology
